Evvy announces $40M Series B led by Catalio Capital Management

Evvy announced a $40 million Series B led by Catalio Capital Management on Sept. 15, 2026. The 2021-founded company offers an at-home metagenomic sequencing test for vaginal microbes and says it serves 100,000+ U.S. patients with 3,000 practitioners. New investors include U.S. Fertility Innovation Fund, Rethink Impact and Muse Capital.